Liu P Y, Turner L, Rushford D, McDonald J, Baker H W, Conway A J, Handelsman D J
Andrology Unit, Royal Prince Alfred Hospital and Department of Medicine (DO2), University of Sydney, Sydney, NSW 2006, Australia.
Hum Reprod. 1999 Jun;14(6):1540-5. doi: 10.1093/humrep/14.6.1540.
In order to evaluate the efficacy and safety of recombinant human follicle stimulating hormone (r-hFSH) in combination with urinary human chorionic gonadotrophin (HCG) to induce spermatogenesis and fertility in gonadotrophin-deficient men, we conducted a prospective, open, non-comparative multicentre study in two Australian academic medical centres. Ten men with gonadotrophin deficiency requiring induction of spermatogenesis and fertility were treated with HCG for 3-6 months followed by the s.c. self-administration of injections of r-hFSH in combination with HCG for 18 months. Among the eight men who commenced r-hFSH treatment, seven demonstrated sperm output at a median of 6 months and five achieved the target sperm output of 1. 5x10(6) per ml at a median of 9 months of FSH treatment. Mean testicular volume increased by 4.2 ml during FSH treatment. Three men produced pregnancies in their partners, two of which resulted in the birth of healthy babies and a third patient's partner had a miscarriage. We conclude that r-hFSH is well tolerated and effective in inducing testis growth, spermatogenesis and fertility in gonadotrophin-deficient men. The efficacy of r-hFSH seems comparable with urinary FSH at restoring normal fertility in gonadotrophin-deficient men.
为了评估重组人促卵泡激素（r-hFSH）联合尿源性人绒毛膜促性腺激素（HCG）诱导促性腺激素缺乏男性精子发生及生育能力的疗效和安全性，我们在澳大利亚的两家学术医学中心开展了一项前瞻性、开放性、非对照的多中心研究。10例需要诱导精子发生及生育能力的促性腺激素缺乏男性先接受3 - 6个月的HCG治疗，随后皮下自行注射r-hFSH联合HCG共18个月。在开始r-hFSH治疗的8例男性中，7例在FSH治疗中位数6个月时出现精子输出，5例在FSH治疗中位数9个月时达到每毫升1.5×10⁶的目标精子输出量。FSH治疗期间平均睾丸体积增加4.2毫升。3例男性的伴侣怀孕，其中2例诞下健康婴儿，第3例患者的伴侣发生流产。我们得出结论，r-hFSH在促性腺激素缺乏男性中耐受性良好，能有效诱导睾丸生长、精子发生及生育能力。在恢复促性腺激素缺乏男性的正常生育能力方面，r-hFSH的疗效似乎与尿促性素相当。
